Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQ vs IM Testosterone in Transgender Male Adolescents
NCT03864913Phase 1Completed
- Sponsor
- Oregon Health & Science University
- Start
- Jan 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of testosterone in gender dysphoria (GD) (3 arms), sponsored by Oregon Health & Science University. Primary endpoint: Serum testosterone level at 6 months. Started Jan 2018; status: completed.
02
Drugs
testosterone
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on NCT03864913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03864913.